{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arformoterol",
    "query": {
      "intervention": "Arformoterol"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 167,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arformoterol&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T22:21:21.272Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01980615",
      "title": "Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Inhaled BGF (PT010) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Inhaled BGF (PT010) Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Inhaled BGF (PT010) Dose 3",
          "type": "DRUG"
        },
        {
          "name": "Inhaled GFF (PT003)",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Symbicort Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Symbicort Dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 84,
      "start_date": "2013-11",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-14",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01980615"
    },
    {
      "nct_id": "NCT01551888",
      "title": "Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Aclidinium/formoterol 400/12μg",
          "type": "DRUG"
        },
        {
          "name": "Formoterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-01",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2017-02-14",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 1,
      "location_summary": "Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01551888"
    },
    {
      "nct_id": "NCT07525375",
      "title": "A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "GP MDI",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "BFF MDI",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo MDI",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Years to 11 Years"
      },
      "enrollment_count": 69,
      "start_date": "2026-04-14",
      "completion_date": "2029-05-23",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 15,
      "location_summary": "Bakersfield, California • Lancaster, California • Long Beach, California + 12 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07525375"
    },
    {
      "nct_id": "NCT02196714",
      "title": "PK Study of PT003 and PT001 in Japanese Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02196714"
    },
    {
      "nct_id": "NCT01854658",
      "title": "Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "GFF MDI (PT003)",
          "type": "DRUG"
        },
        {
          "name": "GP MDI (PT001)",
          "type": "DRUG"
        },
        {
          "name": "FF MDI (PT005)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 1615,
      "start_date": "2013-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 113,
      "location_summary": "Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854658"
    },
    {
      "nct_id": "NCT00633776",
      "title": "Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "COPD",
        "Chronic Bronchitis",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "formoterol fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-03",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00633776"
    },
    {
      "nct_id": "NCT02157935",
      "title": "Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD Patients"
      ],
      "interventions": [
        {
          "name": "Symbicort",
          "type": "DRUG"
        },
        {
          "name": "Formoterol turbohaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Symbicort pMDI",
          "type": "OTHER"
        },
        {
          "name": "Placebo for Formoterol Turbohaler",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "40 Years to 95 Years"
      },
      "enrollment_count": 2026,
      "start_date": "2014-06-27",
      "completion_date": "2016-02-08",
      "has_results": true,
      "last_update_posted_date": "2017-11-07",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 224,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02157935"
    },
    {
      "nct_id": "NCT02500784",
      "title": "Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "Formoterol A",
          "type": "DRUG"
        },
        {
          "name": "Formoterol B (placebo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Palo Alto Veterans Institute for Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-01",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500784"
    },
    {
      "nct_id": "NCT00747318",
      "title": "A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "SKP FlutiForm HFA pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SkyePharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2008-09",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2011-06-23",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Orange County, California • Colorado Springs, Colorado + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orange County",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Valrico",
          "state": "Florida"
        },
        {
          "city": "Elizabeth City",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00747318"
    },
    {
      "nct_id": "NCT06744374",
      "title": "A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "BGF",
          "type": "DRUG"
        },
        {
          "name": "MITT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 22369,
      "start_date": "2024-02-29",
      "completion_date": "2024-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-09-03T22:21:21.272Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06744374"
    }
  ]
}